Omaha、NEにおける前立腺がんの臨床試験
Omahaとその周辺地域（約30マイル以内）の拠点で、前立腺がんに関する27件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
被験者募集中第2相
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9マイル先
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
被験者募集中第1/2相
- Urology Cancer Center, PC, Omaha
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
被験者募集中第3相
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0026), Omaha
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
被験者募集中第2/3相
- Nebraska Cancer Specialists, Omaha
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
被験者募集中第3相
- Nebraska Cancer Specialists, Omaha
PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer
被験者募集中第2相
- University of Nebraska Medical Center, Omaha
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
被験者募集中第1相
- XCancer, Omaha
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
被験者募集中第3相
- XCancer Omaha LLC, Omaha
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
被験者募集中第3相
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9マイル先
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
被験者募集中第1/2相
- Research Site, Omaha
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
被験者募集中第3相
- Research Site, Omaha
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
被験者募集中第2相
- XCancer Omaha, Omaha
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
被験者募集中第1/2相
- Nebraska Cancer Specialists, Omaha
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
被験者募集中第3相
- Alegent Health Bergan Mercy Medical Center, Omaha
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
被験者募集中第2相
- University of Nebraska Medical Center, Omaha
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
被験者募集中第3相
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
Integrated Cancer Repository for Cancer Research
被験者募集中観察研究健康なボランティア歓迎
- Methodist Estabrook Cancer Center, Omaha
- Nebraska Methodist Health System, Omaha
- University of Nebraska Medical Center, Omaha
- 他1件
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
被験者募集中第1相
- Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
- XCancer Omaha / Urology Cancer Center, Omaha
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
被験者募集中第4相
- Urology Cancer Center PC, Omaha
- Nebraska Cancer Specialists, Omaha
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
被験者募集中第1/2相
- XCancer Omaha / Urology Cancer Center, Omaha
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
被験者募集中第1相
- Research Site, Omaha
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
被験者募集中第2相
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
- 他3件
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
被験者募集中第3相
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9マイル先
High-dose Brachytherapy Boost With Stereostatic Body Radiation Therapy to Intermediate or Higher Risk Prostate Cancer
被験者募集中
- University of Nebraska Medical Center, Omaha
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Omaha
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
被験者募集中第3相
- Nebraska Methodist Hospital, Omaha
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- 他1件
他の都市における前立腺がんの試験
- New York City, NY103件の研究
- Houston, TX76件の研究
- Los Angeles, CA61件の研究
- Boston, MA59件の研究
- St. Louis, MO46件の研究
- Chicago, IL45件の研究
- San Francisco, CA45件の研究
- Philadelphia, PA44件の研究
- Baltimore, MD43件の研究
- Nashville, TN42件の研究
- Seattle, WA42件の研究
- Washington, DC38件の研究
Omahaにおける他の研究
- 非小細胞肺癌24件の研究
- 乳がん22件の研究
- 大腸癌18件の研究
- がん（全種類）18件の研究
- 多発性骨髄腫16件の研究
- 非ホジキンリンパ腫14件の研究
- 卵巣がん14件の研究
- 膵臓がん14件の研究
- 頭頸部扁平上皮癌13件の研究
- 心不全13件の研究
- 転移性癌13件の研究
- 腎臓がん（腎細胞がん）12件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。